Best Cardiac and Vascular Disorders Companies in Ireland
The 39 best Cardiac and Vascular Disorders companies in Ireland in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Juvenescence.
Ranked: Best Cardiac and Vascular Disorders companies in Ireland
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Juvenescence Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health | $214M | 16 mo ago | 38 | Greg Bailey Co-Founder & CEO | WordPressApple iCloud MailMicrosoft 365+21 | Series B | 2 patents Medical informatics: computer-based health data analysis and management systems | — |
| 2 | Vivasure Medical Developer of polymer implants and delivery systems | $92M | 41 mo ago | 44 | Chris Martin Co-Founder & CTO | WordPressPleskMySQL+18 | Acquired | 105 patents Percutaneous vascular access closure devices and implantable arteriotomy sealing systems | — |
| 3 | Amarin Developer of therapies to treat cardiovascular disorders | $70M | 115 mo ago | 365 | Patrick Holt CEO & President | DrupalApple iCloud MailPHP+21 | Public | 31 patents Combining omega‑3 fatty acids with hydroxy‑statin derivatives for cardiovascular drugs | — |
| 4 | arravasc limited ArraVasc Limited designs, manufactures, and markets devices for interventional clinicians. | $51M | 187 mo ago | 36 | — | — | Deadpooled | 5 patents Drug‑eluting angioplasty balloon devices and their delivery catheter systems | — |
| 5 | LUMA Vision Developer of interventional cardiac imaging devices | $42M | 32 mo ago | 50 | Fionn Lahart Co-Founder and Chief Executive Officer | WordPressMySQLPHP+16 | Series A | 10 patents Advanced ultrasound imaging and patient-specific anatomical reconstruction for medical diagnostics | — |
| 6 | 4TECH Developer of a transcatheter system for treating tricuspid regurgitation | $36M | 127 mo ago | 23 | — | — | Deadpooled | — | — |
| 7 | CroiValve Developer of a percutaneous device for treating tricuspid regurgitation | $32M | 14 mo ago | 28 | Lucy Okeeffe Co-Founder & CEO | WordPressMySQLPHP+17 | Series B | 16 patents Cardiac valve prosthesis delivery and anti‑migration implantation technologies | — |
| 8 | WhiteSwell Developer of devices for treating acute decompensated heart failure | $30M | 92 mo ago | 33 | — | WordPressMySQLPHP+18 | Series B | — | — |
| 9 | Neuravi Endovascular device for stroke | $28M | 106 mo ago | 33 | — | — | Acqui-Hired | 827 patents Neurovascular endovascular clot removal devices and aspiration catheters. | — |
| 10 | Vasorum Developer of an arterial closure device | $7M | 66 mo ago | 16 | — | — | Series A | 10 patents Surgical wound closure and tissue coupling devices for fluid management | — |
| 11 | Versono Developer of therapeutic solutions to treat peripheral arterial disease | $7M | 52 mo ago | — | Finbar Dolan Founder & CEO | WordPressMySQLPHP+19 | Series A | — | — |
| 12 | LaNua Medical Developer of image-guided technologies for safe and effective endovascular embolization solutions | $6M | 20 mo ago | — | Cormac Farrelly Chief Medical Officer and Co-founder LaNua Medical | — | Seed | — | — |
| 13 | InVera Medical Manufacturer of medical devices for the office-based treatment of chronic venous disease | $5M | 50 mo ago | 12 | Stephen Cox Co-Founder | WordPress Block EditorWordPressMySQL+15 | Seed | — | — |
| 14 | Apica Cardiovascular Transapical surgical access devices | $5M | 187 mo ago | 8 | — | — | Acquired | 29 patents Percutaneous cardiovascular access, stabilization, and tissue puncture sealing devices | — |
| 15 | Embo Medical Vascular embolization device | $4M | 143 mo ago | 6 | — | — | Acquired | 41 patents Minimally invasive vascular embolization devices and delivery systems for therapeutic occlusion | — |
| 16 | ProVascTec Developer of cell therapy device to treat cardiovascular complications | $3M | 11 mo ago | — | Noel Caplice Co-Founder | — | Funding Raised | — | 1 award |
| 17 | AuriGen Medical Developer of trans-septal implant to treat atrial fibrillation | $3M | 39 mo ago | 27 | John Thompson Co-Founder & CEO | — | Series A | 27 patents Percutaneous vascular occlusion and catheter‑delivered implant delivery systems | 1 award |
| 18 | AtriAN Developing the device that targets to atrial fibrillation | $3M | 52 mo ago | 3 | Ken Coffey Co-Founder | — | Seed | — | — |
| 19 | EMBA Medical Developer of smart devices for the treatment of cardiac health diseases | $2M | 69 mo ago | 6 | — | — | Deadpooled | 16 patents Endovascular occlusion and embolization devices for vascular sealing and neurovascular treatment | — |
| 20 | Marvao Medical Venous Catheters based on a technology to create a natural barrier at the catheter exit site | $2M | 186 mo ago | 3 | Chris Davey Co-Founder & CEO | — | Seed | 27 patents Deformable, modular implantable medical devices for orthopedic and soft‑tissue applications | — |
Top 12 Cardiac and Vascular Disorders companies in Ireland
#1
Series B · Dublin, Leinster · founded 2017 · 38 employees$213.9Mraised▾
Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health. The company offers keto-diet-based exogenous ketone which helps in metabolic switches and provides anti-aging properties and protection from other age-related diseases like neurodegenerative diseases, immunosenescence & cell damage. The product is C6 Ketone Di-Ester which can raise the levels of ketones in the blood to generate ketosis.
- May 2025Series B$76M
- Sep 2019Series B—
- Aug 2019Series B$100M
- Jan 2019Series B$46M
#2
Series B · Dublin, Leinster · founded 2016 · 28 employees$32.1Mraised▾
Developer of a percutaneous device for treating tricuspid regurgitation. The device seals the gap between the valve leaflets preventing regurgitation. The device is delivered through a vein and into the right heart, restoring the function of the tricuspid valve.
- Jul 2025Grant (prize money)$2.9M
- Jul 2025Series B$11.8M
- Aug 2024Series B$16M
- Feb 2022Series A$10.9M
#3
Funding Raised · Galway, Connaught · founded 2021$2.9Mraised▾
Developer of cell therapy device to treat cardiovascular complications. The company leverages the paracrine mechanism of stem cells to develop cell-therapy delivery devices for intravascular placement upstream of blood vessels.
- Oct 2025Grant (prize money)$2.9M
#4
Seed · Galway, Connaught · founded 2024$6.3Mraised▾
Developer of image-guided technologies for safe and effective endovascular embolization solutions. It develops solutions for problems in embolization, a minimally invasive procedure used to treat internal bleeding or tumors. Its technology blocks blood flow to select tissue while enabling targeted therapeutic delivery distally, aimed at reducing the risk of side effects. The emerging technology is designed to block blood flow and offer a solution for unwanted embolization reflux. The device is adaptable for use in many areas of the human body to treat multiple disease states.
- Dec 2024Seed$6.3M
#5
Series A · Dublin, Leinster · founded 2017 · 50 employees$42.3Mraised▾
Developer of interventional cardiac imaging devices. It offers VERAFEYE that leverages the power of ultrasound for soft tissue imaging through proprietary computational processing, to provide intracardiac and endovascular navigation.
- Dec 2023Series A$22M
- Oct 2021Grant (prize money)—
- Oct 2021Series A$8M
- Oct 2020Grant (prize money)$2.9M
#6
Acquired · Galway, Connaught · founded 2009 · 44 employees$92.1Mraised▾
Vivasure Medical has developed a patented bioabsorbable implant technology and delivery systems. The company has developed a patch-based large-bore percutaneous closure implant using the PerQseal technology. Its implant is CE marked is a fully absorbable implant and percutaneous delivery system for the closure of large arteriotomies in transcatheter procedures.
- Mar 2023Series D$31.9M
- Mar 2023Grant (prize money)—
- May 2022Series D$22.9M
- May 2020Grant (prize money)$2.6M
#7
Series A · Galway, Connaught · founded 2016 · 27 employees$2.9Mraised▾
Developer of trans-septal implant to treat atrial fibrillation. The device is implanted to treat stroke and arrhythmia caused due to atrial fibrillation.
- Jun 2023Grant (prize money)$2.7M
- Jan 2019Grant (prize money)$1.3M
- Jul 2018Grant (prize money)$2.9M
- Jun 2018Series A$2.9M
#8
Public · Dublin, Leinster · founded 1991 · 365 employees$70Mraised▾
Amarin is developing therapies for treating cardiovascular disease. Amarin's lead candidate, AMR101, is currently being studied in two concurrently run pivotal phase III trials. These trials are investigating the efficacy of AMR101 in lowering triglycerides in patients with very high triglycerides and in patients with mixed dyslipidemia who are taking statins.
- Jan 2017Conventional Debt—
- Oct 2009Post IPO$70M
#9
Acqui-Hired · Galway, Connaught · founded 2009 · 33 employees$27.6Mraised▾
Neuravi is developing a platform for treatment of acute ischemic stroke. The EmboTrap revascularization device removes clots from the vascular system. Product is CE Marked but yet to be approved for use in the US.
- Nov 2017Grant (prize money)$484K
- Nov 2016Venture Debt$16.5M
- Jun 2015Series B$21.2M
- Jul 2012Series A$6.4M
#10
Deadpooled · Galway, Galway · founded 2004 · 36 employees$50.5Mraised▾
Developer of catheters designed to treat Coronary Artery Disease (CAD) and bifurcation vascular disease. The company's catheters are drug-eluting ostium protection devices for the treatment of coronary artery lesions located at a bifurcation and ostium, enabling healthcare providers to treat coronary artery diseases.
#11
Seed · Galway, Connaught · founded 2018 · 12 employees$5.3Mraised▾
Manufacturer of medical devices for the office-based treatment of chronic venous disease
- Jun 2022Seed—
- 2022Grant (prize money)—
- Oct 2020Seed$5.3M
- Sep 2019Seed$25K
#12
Deadpooled · Galway, Connaught · founded 2010 · 23 employees$36Mraised▾
4TECH has developed a proprietary transcatheter system for repairing the tricuspid valve and reduce tricuspid regurgitation. The TriCinch coil system is an FDA approved anteroposterior annuloplasty solution which is placed in the ventricular epicardium to target the annular dilatation and restore ventricular shape.
- Jan 2016Series B$29M
- Dec 2011Series A$7M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Cardiac and Vascular Disorders coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding flat · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.